A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors

Protein kinases have emerged as one of the major drug target classes that are amenable to the development of small molecule inhibitors. They share a conserved structural similarity in the region of the ATP binding site, where most inhibitors interact. Using a pharmacophore approach, we have explored the features of protein-ligand interactions for a set of 220 kinase crystal structures from the Protein Data Bank (PDB). The resulting "pharmacophore map" shows the interactions made by all ligands with their receptors simultaneously. This gives insight that has been applied in the design of kinase screening sets and combinatorial libraries. An algorithm is described that scores small molecule structures for goodness of fit to the resulting binding site description obtained from the analysis. The algorithm identifies a pose that is close to the crystal structure pose for the majority of ligands, with only the 2D chemical structure as input and no knowledge of the crystal structure from which it was derived. Application of the algorithm to a test screening set gave a useful enrichment of active compounds.

[1]  P. Workman,et al.  Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets , 2006 .

[2]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[3]  Zhan Deng,et al.  Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. , 2005, Journal of medicinal chemistry.

[4]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[5]  Jeffrey Jie-Lou Liao,et al.  Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.

[6]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[7]  Malcolm J. McGregor,et al.  Pharmacophore Fingerprinting. 1. Application to QSAR and Focused Library Design , 1999, J. Chem. Inf. Comput. Sci..

[8]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[9]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[10]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[11]  I. Muegge,et al.  Virtual screening for kinase targets. , 2004, Current medicinal chemistry.

[12]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  B Li,et al.  Creating chemical diversity to target protein kinases. , 2004, Combinatorial chemistry & high throughput screening.

[14]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[15]  Xiaoling Xie,et al.  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. , 2007, Journal of medicinal chemistry.

[16]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[17]  Stephan C. Schürer,et al.  Prospective Exploration of Synthetically Feasible, Medicinally Relevant Chemical Space , 2005, J. Chem. Inf. Model..

[18]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[19]  D. Williams,et al.  Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. , 2004, Current medicinal chemistry.

[20]  Felix Deanda,et al.  Application of the PharmPrint Methodology to Two Protein Kinases , 2004, J. Chem. Inf. Model..

[21]  E. Baker,et al.  Hydrogen bonding in globular proteins. , 1984, Progress in biophysics and molecular biology.

[22]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[23]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[24]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[25]  Malcolm J. McGregor,et al.  Pharmacophore Fingerprinting. 2. Application to Primary Library Design , 2000, J. Chem. Inf. Comput. Sci..

[26]  Alex M Aronov,et al.  Toward a pharmacophore for kinase frequent hitters. , 2004, Journal of medicinal chemistry.

[27]  P. Fischer,et al.  The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. , 2004, Current medicinal chemistry.

[28]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[29]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.